# OPB-201

Source: https://onco.cc/drugs/opb-201/  
OnCo record `opb-201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OPB-201 is an experimental autologous TCR T-cell therapy from Outpace Bio, in phase 1 trials for recurrent endometrial cancer, platinum-resistant ovarian cancer and other solid tumours.

## Summary

OPB-201 is an autologous TCR T-cell therapy from Outpace Bio. Autologous T cells carrying an optimised T-cell receptor for a PRAME-derived peptide plus a designed protein that boosts their potency. Its furthest stage is phase 1, for recurrent endometrial cancer, platinum-resistant ovarian cancer and other solid tumours. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: OPB-201
- Modality: Autologous TCR T-cell therapy
- Mechanism: Autologous T cells carrying an optimised T-cell receptor for a PRAME-derived peptide plus a designed protein that boosts their potency.

## Sources

- Outpace Bio: outpacebio.com: https://outpacebio.com/our-science
- Outpace Bio: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07664735
- ClinicalTrials.gov: trials of OPB-201: https://clinicaltrials.gov/search?intr=OPB-201

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- targets: [PRAME](https://onco.cc/targets/prame/)
- companies: [Outpace Bio](https://onco.cc/companies/outpace-bio/)
- trials: [A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.](https://onco.cc/trials/nct07664735/)

---
JSON: https://onco.cc/api/v1/entities/opb-201.json